Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy.
Shiwen KoayEkawat VichayanratFion BremnerJalesh N PanickerBethan LangMichael P LunnLaura WatsonGordon T IngleEllen Merete HagenPatricia McNamaraLeslie JacobsonVincenzo ProviteraMaria NolanoAngela VincentChristopher J MathiasValeria IodicePublished in: Annals of neurology (2021)
Patients with autoimmune autonomic ganglionopathy demonstrated objective evidence of widespread sympathetic and parasympathetic autonomic failure, with significant improvements after immunotherapy. Quantitative autonomic biomarkers should be used to define initial deficits, guide therapeutic decisions, and document treatment response. ANN NEUROL 2021;89:753-768.